Tamil Nadu regains 39 super speciality medical seats for the second round of counselling
In Tamil Nadu, 50% of seats in super speciality courses in government medical colleges are reserved for in-service candidates, totalling 215.
The first round of counselling for the State quota in-service candidates was completed on May 27. The State had then requested the Directorate General of Health Services (DGHS) to indicate the schedule to conduct the second round of counselling to allow upgradation for the in-service candidates.
However, in early June, the DGHS asked the State to revert the vacant in-service seats to the Medical Counselling Committee (MCC) to include them in the All-India seat matrix since the second round of All-India Counselling had started.
Following this, 145 seats meant for in-service candidates were surrendered for the AIQ, sparking criticism among a section of government doctors, since it went against the 50% reservation for in-service candidates.
Health Minister Ma. Subramanian wrote to the Union Health Minister expressing concern about surrendering unfilled in-service seats to the AIQ without conducting the mandatory second round of counselling at the State-level.
He also sought his intervention to ensure that all 50% seats earmarked for in-service candidates under the State quota are retained and made available for the second round of State-level super speciality counselling.
However, with the second round of AIQ counselling completed, 39 seats are being surrendered to the State.
Request to MCC
In addition, the State has sought the MCC to return the seats of Tamil Nadu candidates who have gone on to choose seats in institutions such as the All India Institute of Medical Sciences and Jawaharlal Institute of Postgraduate Medical Education and Research through the Institutes of National Importance-Combined Entrance Test, a health official said, adding: 'We have sought returning of such seats so that we could add on to the second round of State counselling.'
A source in the Health Department said all eligible in-service candidates should have been called for the first round of counselling to ensure that more seats were filled.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
4 hours ago
- India.com
NEET UG Counselling 2025: Registration to begin tomorrow; result on..., direct link, steps to register here
NEET UG Counselling 2025: The Medical Counselling Committee (MCC) will be accepting online registrations for NEET UG 2025 counselling from tomorrow, July 21. The counselling will allow candidates to take part in 15% All India Quota (AIQ) medical courses like MBBS, BDS, BSc Nursing, and AYUSH courses. Candidates can register themselves on to the official website of MCC at Following will be the issuing of the seat matrix, list of participating institutes and their counselling brochures. The result for the NEET UG 2025 was announced on June 14. Counselling process for the state quota seats will also commence from July 21 to 30 as per previous MCC notifications, followed by the counselling for AIQ/Deemed/Central institutions from July 30 to August 6. NEET UG Counselling 2025: Eligibility Students who have appeared for the NEET UG 2025 and qualified the exam will be able to be a part of this counselling process. MCC will manage counselling for seats under 15% AIQ quota, 100% seats for institutes like AIIMS, JIPMER, BHU, AMU, ESIC, insured person (IP) quota and other central and deemed universities. NEET UG Counselling 2025: How to register Visit the official MCC website at . Click on the tab that reads 'UG Medical Counselling'. Register/ log in using the required credentials Fill up the application form and pay the application fee Attach required documents like NEET scorecard, photo ID, category certificate, etc. Select your preference combination of college and course. Save the confirmation page for future reference. NEET UG Counselling 2025: schedule for round 1 The schedule includes verification of the seat matrix by the institutes and the National Medical Commission (NMC) from July 18 to 19, 2025. Candidates are required to complete the registration process along with the payment of the fees from July 21 to 28 last by 12:00 PM. This will be followed by the preference filling that will take place from July 22 to 28 last by 11:55 PM. Candidates must keep in mind to lock their choices on July 28 from 4:00PM to 11:55 PM. The seat allotment will take place from July 29 to 30 and results to be issued for the first round on July 31, 2025. After results, selected candidates are required to report to their respective institute from August 1 to 6, for physical verification. The data verification will be scheduled between August 7 to 8 by the institutes. MCC has also instructed the institutes to strictly adhere to the schedule due to limited time available for counselling. They may employ Saturdays, Sundays and Gazetted holidays as working days also.
The Hindu
17 hours ago
- The Hindu
Legal provision needed to ensure journalists' wages, says Sharan Prakash Patil
Journalists today stand as vigilant sentinels of democracy, and protecting their welfare is a responsibility that cannot be overlooked, said Minister for Medical Education and Skill Development Sharan Prakash Patil. He was speaking after inaugurating the 'Press Day' celebrations and L. B. Mahadevappa Memorial award ceremony, organised by the taluk working journalists' association in Sedam of Kalaburagi district on Saturday. Expressing concerns over job security and low wages of journalists, Dr. Patil stressed the need for a legal mechanism at the national level to ensure that journalists receive fair and timely wages. 'A statutory framework for journalists' wages must be initiated by the Union government. The State will consider all genuine demands from the media fraternity,' he added. Expressing concerns over media ownership being increasingly concentrated in the hands of a few wealthy individuals, an outcome of globalisation, Dr. Patil called upon the journalists to maintain neutrality in their reporting. He emphasised that Chief Minister Siddaramaiah's government has been proactive in implementing schemes for the welfare of rural journalists, including free bus passes and the Arogya Sanjeevani health insurance scheme. 'Journalists work under immense stress, and their health must not be neglected. Their hearts must remain strong too. That is why free cardiac check-ups are being organised this weekend at the Jayadeva Institute of Cardiovascular Sciences in Kalaburagi,' Dr. Patil said.
Mint
a day ago
- Mint
Sigachi disaster: The blast must jolt pharma regulators out of their slumber
The 30 June explosion, which ripped through Sigachi Industries Ltd's pharmaceutical plant in Hyderabad, has left the already bruised reputation of India's pharmaceutical manufacturing industry in tatters. The blast—which claimed the lives of 44 workers and critically injured 33 more, with eight officially listed as 'missing"—has once again put the spotlight on shortcomings in occupational safety and GMP (good manufacturing practice) compliance in India's pharmaceutical sector. The industrial accident also exposes the huge gaps in regulatory oversight and enforcement. That can have disastrous consequences because this not only endangers the lives of the workers, but also the lives of residents living near such plants. Besides, poor-quality medicines and formulations pose a serious threat to patient safety and could damage the reputation of India's $65 billion pharmaceutical market. The Sigachi disaster The Sigachi blast is the worst industrial accident in Indian pharma manufacturing in terms of the number of casualties. The unit had not put up the mandatory 'green board", which is supposed to list potentially hazardous material and processes used in the plant, so that emergency services know what they have to deal with, The Hindu reported on 6 July. These details are also supposed to be filed with the fire department, which also wasn't done. And clearly no one bothered to even check. Further, an FIR filed by the family member of a deceased worker claimed that workers had raised concerns about the safety of the equipment—which was allegedly old. Periodic safety inspections of the unit—if they were carried out—should have noted this, if this was indeed the case. A commission of inquiry has been appointed to investigate the accident. But the point is that poor attention to safety and quality is putting at risk India's claim to be the pharmaceutical capital of the world—it's the world's third-largest pharmaceuticals exporter. More importantly, the sector—the fifth-largest contributor to the country's manufacturing gross value added—accounts for a fifth of the world's generic formulations output and three-fifths of global vaccine production. This thriving market is now at risk due to repeated cases of India-made drugs failing to pass regulatory quality control. Chequered track record In May 2024, India's apex drug control authority, Central Drugs Standard Control Organization (CDSCO), put out a list of 50 formulations, used to treat widely prevalent issues ranging from fever to diabetes, which were found to be substandard. That's a pretty routine occurrence. In May 2025, the CDSCO's alert listed 128 formulations as being not of standard quality, while two more were found to be fake. Mind you, only around 3 % of samples are tested, because the state drug control laboratories are severely underfunded, understaffed, and underequipped. In fact, overseas regulators, particularly the US Food and Drugs Administration (FDA) have been far more diligent in inspections and evaluations, although the FDA's actions are confined only to those units that manufacture drugs exported to the US. But that is not an inconsiderable number. India has the largest number of USFDA-approved plants worldwide, excluding the US, at 499. The US has 530 such plants, while Europe has 416. A June 2025 analysis by CARE Ratings found the same troubling issues, which have dogged Indian pharma manufacturing over the years. According to the report, between 2022 and 2025, 33 warning letters were issued to Indian pharma companies. The main reasons included failure to maintain quality and purity (24%), lack of data documentation and rigour (21%),, and unsanitary/unhygienic conditions at the facilities. There were also multiple incidents of regulatory non-compliance, including failure to properly test raw material and failure to use globally validated analytical methods. Perhaps, the most sensational case was of Ranbaxy Laboratories Ltd, which admitted to seven felony counts, including selling adulterated drugs, not reporting that its drugs failed to meet standards, and intentionally lying to the authorities. Ranbaxy, then India's largest generics manufacturer, was forced to pay $500 million in fines and eventually was forced to sell out to a Japanese pharma company. A national priority Nearly two decades on, similar incidents are cropping up with alarming regularity, pointing to systemic failures that need to be addressed with urgency. These include a chronically under-resourced regulatory system, lack of adequate infrastructure and technical knowledge among regulators, endemic corruption, and weak enforcement of existing rules and laws. Part of the problem stems from the industry's fragmented nature. Due to policy and licensing issues, most of India's 10,000-odd pharma manufacturing plants fall in the MSME space. They lack the capital to adequately invest in technology, GMP compliance, and worker training. Most of the workers killed in the Sigachi incident, for instance, were poor migrant workers from Bihar. India needs to urgently address these systemic issues—particularly in view of China's strides in this sector—if it is not to lose its preeminent place in the global pharma sector. It must be a national priority where both states and the Centre work in tandem to adequately support the regulatory structure—in terms of money, human, and technical resources.
